|
1
|
Lortet-Tieulent J, Soerjomataram I, Ferlay
J, Rutherford M, Weiderpass E and Bray F: International trends in
lung cancer incidence by histological subtype: Adenocarcinoma
stabilizing in men but still increasing in women. Lung Cancer.
84:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tissot C, Couraud S, Tanguy R, Bringuier
PP, Girard N and Souquet PJ: Clinical characteristics and outcome
of patients with lung cancer harboring BRAF mutations. Lung Cancer.
91:23–28. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Antonio C, Passaro A, Gori B, Del
Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F:
Bone and brain metastasis in lung cancer: Recent advances in
therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jung RS, Mittal BR, Santhosh S, Sood A,
Bhattacharya A and Kapoor R: Is femoral uptake of Tc99m-methylene
diphosphonate on bone scintigraphy in bronchogenic carcinoma an
alarming sign: A case report and brief review of literature? Lung
India. 31:280–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Henry D, Vadhan-Raj S, Hirsh V, von Moos
R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, et
al: Delaying skeletal-related events in a randomized phase 3 study
of denosumab versus zoledronic acid in patients with advanced
cancer: An analysis of data from patients with solid tumors.
Support Care Cancer. 22:679–687. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Murakami H, Yamanaka T, Seto T, Sugio K,
Okamoto I, Sawa T, Hirashima T, Takeda K, Atagi S, Fukuoka M, et
al: Phase II study of zoledronic acid combined with docetaxel for
non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci.
105:989–995. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dimitroulis IA, Dervas A, Vasileiou S and
Toumbis M: Comparative efficacy of ibandronic acid vs. Zoledronic
acid in lung cancer patients with skeletal metastases. Do they
alleviate the patient? J Thorac Oncol. 9:S203–S204. 2014.
|
|
10
|
LeVasseur N, Clemons M, Hutton B, Shorr R
and Jacobs C: Bone-targeted therapy use in patients with bone
metastases from lung cancer: A systematic review of randomized
controlled trials. Cancer Treat Rev. 50:183–193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miller RE, Jones JC, Tometsko M, Blake ML
and Dougall WC: RANKL inhibition blocks osteolytic lesions and
reduces skeletal tumor burden in models of non-small-cell lung
cancer bone metastases. J Thorac Oncol. 9:345–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moyer VA: U.S. Preventive Services Task
Force: Screening for lung cancer: U.S. Preventive Services Task
Force recommendation statement. Ann Intern Med. 160:330–338. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moolgavkar SH, Holford TR, Levy DT, Kong
CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, et al:
Impact of reduced tobacco smoking on lung cancer mortality in the
United States during 1975–2000. J Natl Cancer Inst. 104:541–548.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Humphrey L, Deffebach M, Pappas M, Baumann
C, Artis K, Mitchell JP, Zakher B, Fu R and Slatore C: Screening
for Lung Cancer: Systematic Review to Update the U.S. Preventive
Services Task Force Recommendation [Internet]. U.S. Preventive
Services Task Force Evidence Syntheses, formerly Systematic
Evidence Reviews. 157:7062013.
|
|
15
|
Barrett-Lee P, Casbard A, Abraham J, Hood
K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R,
Griffiths G, et al: Oral ibandronic acid versus intravenous
zoledronic acid in treatment of bone metastases from breast cancer:
A randomised, open label, non-inferiority phase 3 trial. Lancet
Oncol. 15:114–122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hendriks LE, Hermans BC, van den
Beuken-van Everdingen MH, Hochstenbag MM and Dingemans AM: Effect
of bisphosphonates, denosumab, and radioisotopes on bone pain and
quality of life in patients with non-small cell lung cancer and
bone metastases: A systematic review. J Thorac Oncol. 11:155–173.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie F, Li P, Gong J, Zhang J and Ma J: The
bisphosphonate zoledronic acid effectively targets lung cancer
cells by inhibition of protein prenylation. Biochem Biophys Res
Commun. 467:664–669. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silva SC, Wilson C and Woll PJ:
Bone-targeted agents in the treatment of lung cancer. Ther Adv Med
Oncol. 7:219–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu J, Huang W, Zhou R, Jia S, Tang W, Luo
Y and Zhang J: Bisphosphonates in the treatment of patients with
metastatic breast, lung, and prostate cancer: A Meta-analysis.
Medicine (Baltimore). 94:e20142015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luedders DW, Steinhoff J, Thill M, Rody A
and Bohlmann MK: Lack of difference in acute nephrotoxicity of
intravenous bisphosphonates zoledronic acid and ibandronate in
women with breast cancer and bone metastases. Anticancer Res.
35:1797–1802. 2015.PubMed/NCBI
|
|
21
|
Qaseem A, Forciea MA, McLean RM and
Denberg TD; Clinical Guidelines Committee of the American College
of Physicians: Treatment of low bone density or osteoporosis to
prevent fractures in men and women: A clinical practice guideline
update from the American College of Physicians. Ann Intern Med.
166:818–839. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jamil K, Zacharin M, Foster B and Munns
CF: Protocol for a randomised control trial of bisphosphonate
(zoledronic acid) treatment in childhood femoral head avascular
necrosis due to Perthes disease. BMJ Paediatrics Open.
1:e0000842017.http://bmjpaedsopen.bmj.com/content/1/1/e000084
View Article : Google Scholar : PubMed/NCBI
|
